mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian | MicrobiomeTrials← Back to trialsNCT02208375
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2014-11-11Est. Completion: 2028-06-30
Enrollment target: 159 participants Locations- M D Anderson Cancer Center, Houston, Texas, United States
Other microbiome trials you might be interested in
Breast Cancer
This study will explore new screening methods for early detection of breast and ovarian cancer in women at high risk for…
Bethesda, United States
Breast CancerOvarian Cancer
This study will evaluate women who are at increased genetic risk of developing ovarian cancer because they or a close re…
Bethesda, United States